Neumora Therapeutics, Inc.
NMRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Neumora Therapeutics, Inc. focuses on Biotechnology services and products. Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in. Valued at $298.3M, NMRA is a micro-cap name in its sector. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Market Cap
$298.3M
Beta
2.77
P/E (TTM)
—
P/E (Fwd)
-2.18
EPS (TTM)
$-1.33
EPS (Fwd)
$-0.74
ROE
-148.7%
ROA
-66.4%
Cash
$147.1M
Total Debt
$53.4M
Free CF
-$108.3M
52W Change
-13.0%
Annual Financials
Cash vs Debt
With $147.1M in cash and $53.4M in debt, NMRA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$108.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -148.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.77 means NMRA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, NMRA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Neumora Therapeutics, Inc. and its sector.